 CAMBRIDGE, Mass.--BUSINESS WIRE--bluebird bio, Inc. Nasdaq: BLUE announced the launch in Germany of ZYNTEGLOTM autologous CD34 cells encoding βA-T87Q-globin gene, a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia TDT who do not have a β0β0 genotype, for whom hematopoietic stem cell HSC transplantation is appropriate but a human leukocyte antigen HLA-matched related HSC donor is not available. This is the first time ZYNTEGLO is commerci 